在患有类风湿性关节炎和最近被诊断为乳腺癌的患者中利用生物疾病修饰性抗风湿疗法
Juan I Ruiz1, Xiudong Lei1, Chi-Fang Wu1
1Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Arthritis care & research
|January 25, 2024
概括
在乳腺癌 (BC) 诊断后,在风湿性关节炎 (RA) 患者中使用的生物修饰性抗风湿药物 (bDMARD) 保持稳定. 之前使用bDMARD是继续治疗的最强预测因素,而先进的BC阶段与较低的利用率有关.
科学领域:
- 类风湿病学 类风湿病学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 生物修饰性抗风湿药物 (bDMARDs) 是用于类风湿性关节炎 (RA) 的免疫抑制剂.
- 有关bDMARDs对RA癌症患者瘤免疫力的影响存在担忧.
- 了解癌症诊断后bDMARD使用趋势对于患者管理至关重要.
研究的目的:
- 描述乳腺癌 (BC) 诊断后的RA患者bDMARDs的使用趋势.
- 在这个患者群体中确定与bDMARD使用相关的因素.
主要方法:
- 从2008年起使用非识别索赔数据库 (Optum CDM,SEER Medicare,TCR Medicare) 进行回顾性队列研究.
- 在BC诊断后三年内使用bDMARD的评估.
- 多变量后勤回归用于评估bDMARD利用的预测因素.
主要成果:
- 在BC诊断之前和之后,bDMARD的使用情况保持一致 (大约. 诊断前的27-28%,诊断后的24-26%).
- 之前使用bDMARD是利用率最强的预测因素 (OR>18在两个队列).
- 先进的BC阶段 (区域/远程) 与bDMARD在SEER/TCR-Medicare中使用率较低有关.
结论:
- 自2008年以来,bDMARD在RA患者最近的BC使用量没有增加.
- 以前的bDMARD使用是BC诊断后继续治疗的主要决定因素.
- 葡萄糖皮质激素的使用仍然很高,这表明正在进行的炎症性疾病管理.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


